Moderna Signs $18.4 Billion in Vaccine Sales

Mandatory Credit: Photo by Pavlo Gonchar/SOPA Images/Shutterstock (11554233a)In this photo illustration, vials seen displayed in front of the Food and Drug Administration (FDA) of the United States and Moderna biotechnology company's logos.
Pavlo Gonchar/SOPA Images/Shutterstock / Pavlo Gonchar/SOPA Images/Shutterstock

Moderna (NYSE: MRNA) had two big announcements today in its quarterly earnings report, according to Bloomberg News. The first is that it has signed agreements worth $18.4 billion in 2021 to sell its Covid-19 vaccine in the United States and elsewhere. The company is in negotiations for more vaccine deals, so its 2021 revenues are likely to be in line with or better than expectations.

See: Stocks Get a Boost From Moderna Vaccine News as It Steals Pfizer’s Spotlight
Find: Country Legend Dolly Parton Helped Fund Moderna’s ‘Impressive’ COVID-19 Vaccine

The financial markets had been expecting disappointing earnings because of the costs involved with vaccine development, production and distribution. And they were disappointing, coming in at a loss of $0.69 per share compared to analyst expectations for a loss of $0.25 per share. Revenue was much stronger than expected, however, at $570.7 million compared to estimates of $326.6 million.

Moderna  is making the transition from focusing on biotech research to becoming a full-fledged niche pharmaceutical company, so the market responded positively despite the larger than expected loss.

Building Wealth

See: Biden Administration Orders 200 Million Additional Vaccines
Find: How to Book Vaccines at Major Pharmacies

 

In addition to the earnings, Moderna announced that Tal Zaks, the company’s chief medical office, would be resigning in the fall. Zaks developed the RNA technology that led to the effective Covid vaccine. In the meantime, Moderna is looking to hire a new medical officer who has experience with large-scale, global product commercialization as the company continues its growth.

More from GOBankingRates

About the Author

Ann Logue is a writer specializing in business and finance. Her most recent book is The Complete Idiot’s Guide: Options Trading (Alpha 2016). She lives in Chicago.

Untitled design (1)
Close popup The GBR Closer icon

Sending you timely financial stories that you can bank on.

Sign up for our daily newsletter for the latest financial news and trending topics.

Loading...
Please enter an email.
Please enter a valid email address.
There was an unknown error. Please try again later.

For our full Privacy Policy, click here.